商业快报

DeepMind spin-off aims to halve drug discovery times following Big Pharma deals
谷歌旗下Isomorphic Labs将把药物发现时间缩短一半

Chief of Google’s AI unit and Isomorphic Labs spells out targets following $3bn Eli Lilly-Novartis partnerships
在与礼来和诺华达成30亿美元合作之后,DeepMind和Isomorphic Labs的负责人哈萨比斯制定了上述目标。
Demis Hassabis, who founded Google DeepMind and runs its drugs offshoot Isomorphic Labs, says the goal is to cut initial stage from about 5 years to 2

The head of Google DeepMind believed its drug discovery spinout would halve the time taken to find new medicines, attracting the attention of the world’s biggest pharmaceutical companies which are looking to artificial intelligence to revolutionise the lengthy process.

谷歌DeepMind公司的负责人认为,该公司的药物研发部门将把寻找新药的时间缩短一半,这吸引了manbetx app苹果 最大制药公司的注意,这些公司正寻求用人工智能彻底改变这一漫长的过程。

您已阅读7%(502字),剩余93%(6235字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归manbetx20客户端下载 所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。
设置字号×
最小
较小
默认
较大
最大
分享×